Company Description
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on developing therapies to treat T cell-driven inflammatory diseases.
The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.
Its lead product candidate is CBP-201, an antibody to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis (AD) and asthma.
The company's product candidates also comprise CBP-307, a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis; and CBP-174, a peripherally acting antagonist of histamine receptor 3 in development for the treatment of pruritus associated with skin inflammation.
Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.
| Country | China |
| Founded | 2012 |
| IPO Date | Mar 19, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 81 |
| CEO | Dr. Zheng Wei Ph.D. |
Contact Details
Address: 12265 El Camino Real, Suite 350 San Diego, California 92130 United States | |
| Phone | 858-727-1040 |
| Website | connectbiopharm.com |
Stock Details
| Ticker Symbol | CNTB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001835268 |
| CUSIP Number | 207523101 |
| ISIN Number | US2075231017 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Wubin Pan M.B.A., Ph.D. | Co-Founder, President and Chairman of the Board of Directors |
| Dr. Zheng Wei Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Steven Chan | Chief Financial Officer |
| Jiang Bian J.D. | General Counsel and Chief Compliance Officer |
| Dr. Lei Sun Ph.D. | Vice President of Biologics and Head of CMC |
| Dr. Raul Collazo Ph.D. | Vice President and Global Head of Medical Affairs |
| Dr. Malinda V. Longphre Ph.D. | Vice President and Head of US Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Apr 16, 2024 | 6-K | Report of foreign issuer |
| Feb 27, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 27, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 13, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | 6-K | Report of foreign issuer |
| Dec 20, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Dec 18, 2023 | 144 | Filing |